The pharmaceutical drugs industry encompasses research, development, manufacturing and marketing of pharmaceutical drugs. Drugs are administered for diagnosis, treatment, and prevention of diseases. Some key categories of pharmaceutical drugs include analgesics, anaesthetics, cough and cold preparations, gastrointestinal drugs, dermatological drugs, genito-urinary drugs, anti-infectives, anti-inflammatory and antirheumatic drugs among others.

 

The global Europe Pharmaceutical Drugs Market is estimated to be valued at US$ 207.6 Bn  or Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

Rising prevalence of chronic diseases is the primary driver estimated to boost growth of Europe Pharmaceutical Drugs Market over the forecast period. As per the latest report published by WHO, cardiovascular diseases, cancer, respiratory diseases and diabetes are the major causes of deaths in Europe. According to global burden of disease study, cardiovascular diseases accounted for over 4 million deaths in Europe in 2016. Chronic diseases are long lasting health issues that require ongoing management such as medications. This in turn is expected to drive demand for pharmaceutical drugs in Europe over the projection period.

The growth of Europe Pharmaceutical Drugs Market is further driven by growing aging population. Europe has the highest percentage of population aged over 65. With aging population increasing vulnerability to chronic diseases will subsequently increase market size of pharmaceutical drugs over the forecast period.

SWOT Analysis
Strength: The European pharmaceutical drugs market benefits from strong governmental support for research and development activities. The region has a highly skilled workforce and state-of-the-art research facilities which support drug innovation. Strict regulations ensure high quality and safety standards are met.

Weakness: Infrastructural challenges and lack of coordinated healthcare systems in some nations increase operational costs. Heavy dependence on importing raw materials from overseas markets leaves the supply chain vulnerable to external disruptions.

Opportunity: Rapid growth of the aging population driving demand for treatments across chronic and lifestyle-related diseases. Untapped potential in emerging Eastern European nations presents an opportunity to expand market reach. Adoption of personalized medicine and new delivery methods offer opportunity for specialized drugs.

Threats: Price controls and austerity measures pose challenges to profitability. High research and development costs for novel drugs increases risk of projects. Increasing competition from lower-cost generic drugs and biosimilars erodes market share of branded products over the long term. Knowledge-based jobs and expertise are vulnerable to offshoring and outsourcing to lower-cost regions.

Key Takeaways
Global Europe Pharmaceutical Drugs Market Size is expected to witness high growth over the forecast period of 2024 to 2031 supported by positive demographic tailwinds and increasing healthcare expenditure across the region. The market size is projected to reach US$ 207.6 billion by 2024 growing at a CAGR of 10% between 2024-2031.

Regional analysis: Germany, France, and the UK represent the largest pharmaceutical drug markets in Europe, collectively accounting for over 50% of the region's pharmaceutical drugs revenue in 2024. Fastest regional growth is expected in Central and Eastern European nations as healthcare infrastructure advances and per capita incomes rise allowing for greater affordability of premium drugs.

Key players operating in the Europe Pharmaceutical Drugs Market are Bank of China, China Development Bank, European Investment Bank, Natixis, Societe Generale, Iberdrola, Banco Santander, Abu Dhabi Islamic Bank, KfW, BNP Paribas, UniCredit, Credit Agricole, DBS Bank, Standard Chartered, NatWest Group. The market remains fairly consolidated with these major players controlling over 75% of regional sales through extensive distribution networks and brand recognition of flagship products.

 

Explore More Related Article On This Topic: https://www.ukwebwire.com/europe-pharmaceutical-drugs-market-scope/

 

Explore More Related Article : https://www.tadalive.com/blog/103937/unveiling-trends-in-the-global-water-and-wastewater-treatment-chemicals-mar/